USC.edu
Are You a Patient?

Toby Maher, MD, PhD

Professor of Clinical Medicine

Image of Toby Maher, MD, PhD
Websites
Is this your profile? Click to edit
Request an Appointment
Email [email protected]
Orcid ID CTSI Profile

Education and Training

  • University of Southampton Medical School, UK — BM — 1998 — Medicine
  • Royal College of Physicians, London, UK — FRCP — 2002 — Internal Medicine
  • Imperial College London, London — MSc — 2004 — Respiratory Medicine
  • University College London, London — PhD — 2009 — Medicine

Research Keywords

  • Idiopathic pulmonary fibrosis
  • Interstitial lung disease
  • Connective tissue disease
  • Biomarkers
  • Clinical Trials
  • Sarcoidosis

Media

Publications

  • Reply to Sun et al.: Interpreting benefit in ELEVATE-IPF. Am J Respir Crit Care Med. 2026 Sep 01; 212(9):2281-2282.. View in PubMed
  • From Mechanisms to Clinical Practice: Introduction to an AJRCCM Special Section on Interstitial Lung Disease. Am J Respir Crit Care Med. 2026 Aug 17.. View in PubMed
  • The Gut Speaks to the Lung: Fecal Microbiota and Survival in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2026 Aug 05.. View in PubMed
  • Single-cell RNA sequencing reveals aberrant airway epithelial-immune cell cross-talk in pulmonary fibrosis. ERJ Open Res. 2026 Jul; 12(4).. View in PubMed
  • Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial. Am J Respir Crit Care Med. 2026 Aug 01; 212(8):1761-1769.. View in PubMed
  • Effect of nerandomilast on survival in patients with pulmonary fibrosis. Eur Respir J. 2026 Jul 30.. View in PubMed
  • Circulating biomarkers in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial. Ann Rheum Dis. 2026 Jul 30.. View in PubMed
  • Gradually, then suddenly: Deconvoluting the natural history of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2026 Jul 16.. View in PubMed
  • Biomarker profiles in idiopathic and progressive pulmonary fibrosis after LPA1 antagonism: exploratory analysis from a phase 2 trial of admilparant. Respir Res. 2026 Jul 15.. View in PubMed
  • Acute exacerbation in fibrotic interstitial lung disease: An International Working Group Report. Am J Respir Crit Care Med. 2026 Jul 14.. View in PubMed

Similar People